Sleep Apnea-Pipeline Review, H1 2016

Sleep Apnea-Pipeline Review, H1 2016

  • Products Id :- GMDHC7769IDB
  • |
  • Pages: 62
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary


Global Markets Direct's, 'Sleep Apnea-Pipeline Review, H1 2016', provides an overview of the Sleep Apnea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sleep Apnea and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Sleep Apnea

The report reviews pipeline therapeutics for Sleep Apnea by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Sleep Apnea therapeutics and enlists all their major and minor projects

The report assesses Sleep Apnea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Sleep Apnea

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Sleep Apnea

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sleep Apnea pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Sleep Apnea Overview 7

Therapeutics Development 8

Pipeline Products for Sleep Apnea-Overview 8

Pipeline Products for Sleep Apnea-Comparative Analysis 9

Sleep Apnea-Therapeutics under Development by Companies 10

Sleep Apnea-Therapeutics under Investigation by Universities/Institutes 11

Sleep Apnea-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Sleep Apnea-Products under Development by Companies 15

Sleep Apnea-Products under Investigation by Universities/Institutes 16

Sleep Apnea-Companies Involved in Therapeutics Development 17

Galleon Pharmaceuticals 17

RespireRx Pharmaceuticals Inc. 18

SK Biopharmaceuticals Co., Ltd. 19

Vivus, Inc. 20

Sleep Apnea-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Combination Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 28

Drug Profiles 29

(phentermine + topiramate) ER-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

CX-1739-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

dexloxiglumide-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

dronabinol-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

GAL-475-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

GAL-475 Backups-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

itriglumide-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

SKL-N05-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecules for Sleep Apnea-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Sleep Apnea-Recent Pipeline Updates 42

Sleep Apnea-Dormant Projects 52

Sleep Apnea-Discontinued Products 53

Sleep Apnea-Product Development Milestones 54

Featured News & Press Releases 54

Feb 29, 2016: RespireRx Pharmaceuticals Announces Removal of FDA Clinical Hold on CX1739 and Initiation of Phase IIA Clinical Trial by March 31, 2016 54

Jun 08, 2015: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of EDS Associated with Narcolepsy or with OSA 54

May 14, 2015: VIVUS Announces Scientific Presentations 54

May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders 56

May 15, 2014: VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists 56

Jul 01, 2013: VIVUS Announces Initial Availability of Qsymia Through Certified Retail Pharmacies 57

Nov 12, 2012: Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules 58

Jan 09, 2012: VIVUS Provides Update on Regulatory Status Of Qnexa 59

Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa 59

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Figures

Number of Products under Development for Sleep Apnea, H1 2016 8

Number of Products under Development for Sleep Apnea-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Comparative Analysis by Early Stage Products, H1 2016 14

Assessment by Monotherapy Products, H1 2016 21

Number of Products by Top 10 Targets, H1 2016 23

Number of Products by Stage and Top 10 Targets, H1 2016 23

Number of Products by Top 10 Mechanism of Actions, H1 2016 25

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 25

Number of Products by Stage and Routes of Administration, H1 2016 27

Number of Products by Stage and Top 10 Molecule Types, H1 2016 28

List of Tables

Number of Products under Development for Sleep Apnea, H1 2016 8

Number of Products under Development for Sleep Apnea-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Late Stage Development, H1 2016 12

Comparative Analysis by Clinical Stage Development, H1 2016 13

Comparative Analysis by Early Stage Development, H1 2016 14

Products under Development by Companies, H1 2016 15

Products under Investigation by Universities/Institutes, H1 2016 16

Sleep Apnea-Pipeline by Galleon Pharmaceuticals, H1 2016 17

Sleep Apnea-Pipeline by RespireRx Pharmaceuticals Inc., H1 2016 18

Sleep Apnea-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 19

Sleep Apnea-Pipeline by Vivus, Inc., H1 2016 20

Assessment by Monotherapy Products, H1 2016 21

Assessment by Combination Products, H1 2016 22

Number of Products by Stage and Target, H1 2016 24

Number of Products by Stage and Mechanism of Action, H1 2016 26

Number of Products by Stage and Route of Administration, H1 2016 27

Number of Products by Stage and Molecule Type, H1 2016 28

Sleep Apnea Therapeutics-Recent Pipeline Updates, H1 2016 42

Sleep Apnea-Dormant Projects, H1 2016 52

Sleep Apnea-Discontinued Products, H1 2016 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Galleon Pharmaceuticals

RespireRx Pharmaceuticals Inc.

SK Biopharmaceuticals Co., Ltd.

Vivus, Inc.

Sleep Apnea Therapeutic Products under Development, Key Players in Sleep Apnea Therapeutics, Sleep Apnea Pipeline Overview, Sleep Apnea Pipeline, Sleep Apnea Pipeline Assessment

select a license
Single User License
USD 2000 INR 146460
Site License
USD 4000 INR 292920
Corporate User License
USD 6000 INR 439380



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]